bims-meluca Biomed News
on Metabolism of non-small cell lung carcinoma
Issue of 2026–11–15
eight papers selected by
the Muñoz-Pinedo/Nadal (PReTT) lab, L’Institut d’Investigació Biomèdica de Bellvitge



  1. Transl Cancer Res. 2026 Oct 30. 15(10): 738
       Background: Hyperglycemia is an independent risk factor for poor prognosis in non-small cell lung cancer (NSCLC), yet the underlying metabolic-oncogenic crosstalk remains incompletely defined. The hexosamine biosynthetic pathway (HBP) senses glucose flux and generates UDP-GlcNAc for O-GlcNAcylation, a post-translational modification catalyzed by O-GlcNAc transferase (OGT). Here we investigate whether and how high glucose exploits OGT-mediated O-GlcNAcylation to fuel NSCLC malignancy.
    Methods: A549 and H1299 NSCLC cells were cultured in normal (5.5 mM) or high (25 mM) glucose. Proliferation, colony formation, migration, invasion, wound healing, and apoptosis were evaluated. OGT and global O-GlcNAc levels were assessed in tumor versus adjacent normal tissues by immunohistochemistry and in cells by western blotting. Stable OGT-knockdown (sh-OGT) lines were generated to dissect functional requirements. PI3K/AKT/mTOR pathway activation was examined by phospho-specific western blotting. The cell lines were tested and confirmed to be mycoplasma-free.
    Results: High glucose significantly enhanced proliferation, clonogenicity, migration, and invasion, and suppressed apoptosis by downregulating Bax and upregulating Bcl-2. OGT and global O-GlcNAcylation were markedly upregulated in NSCLC tissues and in high-glucose-treated cells. OGT silencing abrogated high-glucose-induced malignant phenotypes, restored apoptotic sensitivity, and reverted the Bax/Bcl-2 ratio. Mechanistically, high-glucose-driven O-GlcNAcylation activated PI3K, AKT, and mTOR phosphorylation, whereas OGT knockdown blunted this activation.
    Conclusions: OGT-orchestrated hyper-O-GlcNAcylation is a pivotal conduit linking the hyperglycemic microenvironment to PI3K/AKT/mTOR-dependent NSCLC progression. Targeting OGT-mediated O-GlcNAcylation may offer a precision therapeutic strategy for NSCLC patients with comorbid diabetes or hyperglycemia.
    Keywords:  Non-small cell lung cancer (NSCLC); O-GlcNAc transferase (OGT); O-GlcNAcylation; PI3K/AKT/mTOR pathway; hyperglycemia
    DOI:  https://doi.org/10.21037/tcr-2026-2076
  2. Mol Cell. 2026 Nov 12. pii: S1097-2765(26)00742-2. [Epub ahead of print]
      Perturbed glucose homeostasis is a hallmark of metabolic disease and cancer, and cellular responses to excess glucose are tightly controlled. We report here a lysosomal glucose sensing axis linking the transporter GLUT1 with the lysosomal protein DRAM1. Pathophysiological glucose induces DRAM1 via the MLX/ChREBP transcriptional complex. DRAM1 then binds newly synthesized GLUT1 and promotes its traffic to lysosomes without degradation, reducing surface GLUT1 and acting as a reversible brake on glucose entry. Hexokinase or glucose-6-phosphate (G6P) dehydrogenase disruption weakens DRAM1-GLUT1 complex formation, whereas nicotinamide adenine dinucleotide phosphate(NADPH) oxidase (NOX) inhibition enhances assembly, implicating NADPH as a key metabolic signal downstream of elevated glucose. Sequestration of GLUT1 suppresses glucose uptake and glycolysis and rewires metabolism toward glutamine anaplerosis, creating vulnerability to glutaminase (GLS) inhibition. In vivo, Dram1-/- tumors display a glycolytic metabolite profile, consistent with loss of this brake. Together, these data define an mTORC1- and AMPK-independent lysosomal mechanism that protects metabolic homeostasis under hyperglycemic conditions.
    Keywords:  DRAM1; GLUT1; NADPH; glucose sensing; glutamine anaplerosis; hyperglycemia; lysosomes; metabolism
    DOI:  https://doi.org/10.1016/j.molcel.2026.10.022
  3. Mol Genet Genomics. 2026 Nov 07. pii: 216. [Epub ahead of print]301(1):
      Lung adenocarcinoma (LUAD) is a major non-small cell lung cancer (NSCLC) subtype. Phosphomevalonate kinase (PMVK), a key mevalonate pathway enzyme, promotes LUAD progression. The transcription factor yin yang 1 (YY1) also correlates with LUAD progression; however, their regulatory relationship remains unclear. PMVK was significantly overexpressed in LUAD tissues and radiotherapy-resistant samples; its mRNA and protein levels were higher in the radioresistant (RR) group than in the radiosensitive (RS) group. PMVK knockdown inhibited LUAD cell proliferation, migration, and invasion, elevated ROS, lipid ROS, MDA, and Fe2+ levels, and reduced CoQ10 levels without affecting ferroptosis suppressor protein 1 (FSP1) expression. Under IR, PMVK silencing significantly reduced the survival fraction, increased the proportion of phosphorylated histone H2AX (γ-H2AX) positive cells and elevated apoptosis rates. YY1 directly bound to the PMVK promoter to transcriptionally activate its expression, positively regulating PMVK at both mRNA and protein levels. Transcriptional activation of PMVK by YY1 enhanced LUAD cell proliferation, migration, and invasion, increased the survival fraction, decreased γ-H2AX positive cell ratios and apoptosis rates, lowered ROS, lipid ROS, MDA, and Fe2+ levels, and increased CoQ10 levels, thereby dampening ferroptosis-associated cell death and promoting tumor progression and radiotherapy resistance. Consistently, in vivo xenograft models demonstrated that YY1-mediated PMVK accelerated tumor growth, while simultaneously suppressing DNA damage (γ-H2AX) and lipid peroxidation (4-HNE) induced by irradiation. This study shows that YY1 transcriptionally activates PMVK to modulate radiotherapy resistance and ferroptosis-associated features in LUAD. These findings elucidate LUAD molecular mechanisms and provide a theoretical basis for targeted therapy.
    Keywords:  Ferroptosis; Lung adenocarcinoma; Phosphomevalonate kinase; Radioresistance; Yin yang 1
    DOI:  https://doi.org/10.1007/s00438-026-02532-x
  4. Cell Signal. 2026 Nov 07. pii: S0898-6568(26)00630-3. [Epub ahead of print] 112970
       BACKGROUND: Lung adenocarcinoma (LUAD) accounts for roughly half of all lung cancer cases and novel therapeutic targets remain scarce. Ferroptosis, an iron-dependent form of regulated cell death, offers a promising strategy to combat therapy resistance. Mitochondrial single-stranded DNA-binding protein 1 (SSBP1) is critical for mitochondrial genome stability, but its role in ferroptosis and LUAD progression remains undefined.
    METHODS: We analyzed SSBP1 expression and prognostic value in LUAD using public datasets and clinical specimens. In vitro, we used SSBP1 knockdown/overexpression in LUAD cell lines to assess cell viability, ferroptosis markers (Fe2+, Lipid ROS, MDA, rescue experiments), and mitochondrial function. Transcriptomic sequencing, GSEA, and Western blot were employed to identify the underlying pathway. The therapeutic potential of SSBP1 inhibition combined with the ferroptosis inducer RSL3 was validated in vitro and in a xenograft mouse model.
    RESULTS: High SSBP1 expression is associated with patient prognosis and restrains lipid peroxidation by sustaining ERK-dependent NRF2 nuclear translocation and subsequent HO-1 and GPX4 expression. Loss of SSBP1 impairs this antioxidant signaling axis, leading to increased ferrous ions and lipid ROS within LUAD cells, ultimately sensitized LUAD cells to RSL3, significantly enhancing ferroptosis and inhibiting tumor growth in vivo. Furthermore, mitochondrial damage resulting from ferroptosis in cancer cells exacerbates the mitochondrial apoptosis pathway induced by SSBP1 dysregulation.
    CONCLUSION: SSBP1, a mitochondrial-localized protein associated with LUAD patient prognosis, promotes LUAD progression by inhibiting ferroptosis through the ERK/NRF2/GPX4 axis.
    Keywords:  ERK; Ferroptosis; LUAD; RSL3; SSBP1
    DOI:  https://doi.org/10.1016/j.cellsig.2026.112970
  5. Cancer Lett. 2026 Nov 12. pii: S0304-3835(26)00714-7. [Epub ahead of print] 218950
      Treatment resistance in pleural mesothelioma (PM) is a clinical challenge. Cisplatin-based chemotherapy remains a cornerstone of treatment, but responses are transient as resistant tumor cells drive disease progression. The contribution of the tumor immune microenvironment to chemoresistance is poorly understood so far. Using cisplatin-resistant murine (AB12, PM27) and human (MSTO-211H) PM models combined with transcriptomics, immune profiling and functional assays, we identify a key role for the CCL5-CCR5 axis in shaping an immunosuppressive niche that supports tumor progression. Resistant cells upregulate and secrete high levels of CCL5, leading to enhanced tumor growth in vivo. Immune profiling of tumor microenvironment reveals a marked recruitment of CCR5+ macrophages displaying an immunosuppressive phenotype characterized by reduced inflammatory activity. Mechanistically, tumor-derived CCL5 promotes macrophage recruitment and polarization toward a pro-tumoral state through CCR5 signaling. Disruption of this axis, either by pharmacological inhibition of CCR5 using maraviroc or by genetic silencing of CCL5, reduces macrophage infiltration and significantly impairs tumor progression. These findings reveal microenvironment-driven mechanism of chemoresistance in PM and identify the CCL5-CCR5 axis as a key vulnerability. Targeting this pathway may therefore represent a promising therapeutic strategy to limit the progression of cisplatin-resistant mesothelioma by disrupting the tumor-supportive immune microenvironment.
    Keywords:  CCL5–CCR5 axis; Pleural mesothelioma; chemoresistance; immunosuppression; macrophage polarization; maraviroc; tumor-associated macrophages
    DOI:  https://doi.org/10.1016/j.canlet.2026.218950
  6. Mutat Res. 2026 Nov 04. pii: S1386-1964(26)00027-8. [Epub ahead of print]833 111954
       BACKGROUND: Lung adenocarcinoma (LUAD), the predominant subtype of lung cancer, has limited therapeutic options. Dysregulation of the NF‑κB pathway and M2‑type polarization of macrophages (Macs) drive LUAD progression. GPR87, a member of the GPCR family, is overexpressed in multiple malignancies, including lung cancer, and has been demonstrated to activate NF-κB in pancreatic cancer. However, the function of GPR87 in LUAD and its role in microenvironment remodeling remain unclear.
    METHODS: GPR87 levels in LUAD were analyzed by utilizing the TCGA database. The Kaplan-Meier was utilized for prognostic evaluation. The qPCR and WB were used to assess GPR87 levels in LUAD cell lines. A549 cell GPR87 overexpression model and NCI-H1975 cell GPR87 knockdown model were constructed, and through colony formation, CCK-8, flow cytometry and ELISA, the effects of GPR87 on cell progression, NF-κB signaling pathway and cytokine secretion were explored. A co-cultivation system of A549 cells and THP-1-derived Macs was employed to validate the regulatory effect of the GPR87/NF-κB axis on M2 polarization of Macs via flow cytometry, morphological observation, and ELISA, and validation was also performed using primary Macs derived from PBMCs. In addition, an syngeneic tumor model was established by utilizing C57BL/6 mice, and tumor proliferation, apoptosis, and protein expression were assessed through IHC and TUNEL staining.
    RESULTS: TCGA-LUAD analysis showed that GPR87 was significantly upregulated in LUAD tissues, and GEPIA2 Kaplan-Meier analysis indicated that its high expression was associated with poor overall survival. qPCR and WB further validated the upregulation of GPR87 in LUAD cell lines. In A549 cells, overexpression of GPR87 enhanced colony formation ability and inhibited apoptosis, accompanied by activation of the NF-κB pathway, whereas knockdown of GPR87 produced opposite phenotypic effects. Mechanistic studies showed that the GPR87/NF-κB signaling axis induced THP-1-derived Macs to polarize toward the M2 phenotype, and this result was validated in primary Macs derived from PBMCs. In vivo experiments showed that GPR87 overexpression enhanced the tumorigenic ability of LLC cells, whereas this effect was significantly attenuated by the NF-κB inhibitor BAY 11-7082.
    CONCLUSIONS: GPR87 promotes the malignant phenotype of LUAD cells and induces M2 polarization of Macs via activating the NF-κB signaling pathway. GPR87/NF-κB axis may serve as a novel therapeutic target for LUAD.
    Keywords:  GPR87; Lung adenocarcinoma; M2 polarization of macrophages; NF-κB pathway
    DOI:  https://doi.org/10.1016/j.mrfmmm.2026.111954
  7. Free Radic Res. 2026 Nov 11. 1-26
      Kelch-like ECH-associated protein 1 (KEAP1) is a substrate adaptor of the Cullin-RING E3 ubiquitin ligase complex (CRL3) and a critical regulator of cellular redox homeostasis through controlling nuclear factor erythroid 2-related factor 2 (NRF2) stability. Dysregulation of KEAP1-NRF2 signaling contributes to tumor progression, metabolic adaptation, therapeutic resistance, and ferroptosis evasion. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a promising strategy for targeting therapy-resistant cancers. The canonical KEAP1-NRF2 pathway regulates ferroptosis mainly through antioxidant defense systems, including the solute carrier family 7 member 11 (SLC7A11)-glutathione peroxidase 4 (GPX4) and the ferroptosis suppressor protein 1 (FSP1)-coenzyme Q10 (CoQ10) pathways. Recent studies have revealed that KEAP1 activity is finely regulated by diverse upstream mechanisms, including protein interactions, non-coding RNAs, epigenetic modifications, metabolic signaling, and post-translational modifications. These regulatory networks modulate KEAP1 function and subsequently influence NRF2 activation, redox homeostasis, and ferroptosis susceptibility. This review summarizes the canonical and non-canonical regulatory mechanisms of KEAP1 in ferroptosis, highlighting how multilayered regulation of the KEAP1-NRF2 axis contributes to tumor adaptation, therapeutic resistance, and ferroptosis-based interventions. We further discuss the potential of KEAP1-associated regulatory mechanisms as biomarkers and therapeutic targets for precision cancer therapy.
    Keywords:  Ferroptosis; KEAP1; NRF2,Cancer; Redox homeostasis; Therapy resistance
    DOI:  https://doi.org/10.1080/10715762.2026.2762790
  8. Carcinogenesis. 2026 Nov 12. pii: bgag084. [Epub ahead of print]
      Aberrant glucose metabolism is a hallmark of cancer metabolic reprogramming. The mitochondrial pyruvate dehydrogenase complex (PDC) acts as a central metabolic node that converts pyruvate into acetyl-CoA to sustain oxidative phosphorylation (OXPHOS). In tumor cells, however, overexpressed pyruvate dehydrogenase kinases (PDKs) phosphorylate and inactivate PDC, diverting carbon flux toward glycolysis and driving excessive lactate accumulation. Cumulative evidence demonstrates that microenvironmental lactate not only fuels tumor growth but also reshapes the tumor microenvironment (TME) into an immunosuppressive state that facilitates immune evasion. Conversely, pharmacological PDK inhibition effectively reverses this metabolic shift, depletes intratumoral lactate, restores mitochondrial pyruvate oxidation, and triggers tumor-selective apoptosis. Given these oncogenic and immunosuppressive functions, the PDC/PDK-lactate axis has emerged as a promising therapeutic target, prompting intensive research into the development of small-molecule PDK inhibitors. Here, we critically evaluate the evidence establishing this axis as a key driver of immune evasion. Unlike previous reviews that focused separately on metabolic or immunological aspects, this review uniquely integrates three emerging layers: (i) the isoform-selective functions of PDK1-4 in tumor metabolism and immune modulation; (ii) recently identified histone and non-histone lactylation as a direct epigenetic bridge connecting PDK activity to immune suppression; and (iii) a critical reappraisal of PDK inhibitors, with particular emphasis on the distinction between preclinical efficacy and clinical translation. Finally, we propose that isoform-selective targeting of PDK1 and PDK3, rather than pan-PDK inhibition, combined with immune checkpoint blockade, represents a promising strategy to overcome current therapeutic bottlenecks.
    Keywords:  PDC; PDK; cancer; glycolysis; immune evasion; lactate
    DOI:  https://doi.org/10.1093/carcin/bgag084